ETL CoronaCheck™ PR
Media
A Rapid Antigen Detection Test to Diagnose SARS-CoV-2 Infection Using Exhaled Breath Condensate by A Modified Inflammacheck® Device
Background: The standard test that identifies the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is based on reverse transcriptase-polymerase chain reaction (RT-PCR) from nasopharyngeal (NP) swab specimens. We compared the accuracy of a rapid antigen detection test using exhaled breath condensate by a modified Inflammacheck® device with the standard RT-PCR to diagnose SARS-CoV-2 infection.
CoronaCheck was featured on TG3 in Italy
The Norwegian-English company Zimmer Peacock and the English company Exhalation Technology are developing an accurate and fast rapid test for the coronavirus, that can be used by everyone.
ETL CoronaCheck validated at Norwegian hospital in Vestfold
The new breathalyser test that spots asthma in minutes and may allow doctors to diagnose other respiratory conditions
Cambridge, England, 4 January 2021 – Exhalation Technology Updates on Groundbreaking Clinical Trial for CoronaCheck
New clinical data on the CoronaCheck Covid-19 exhaled breath test shows absolute specificity and sensitivity in a test taking under 5 minutes at under $10.
Exhalation Technology (ETL) Announces New Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Test for Exhaled Breath
Exhalation Technology announces a new clinical study with its novel CoronaCheck™ test for Covid-19, aiming for a sub-5 minute test of high specificity and sensitivity
Exhalation Technology Announces Global Search for Strategic Partners for its Covid-19 Rapid Diagnostic Test
Cambridge, England, 14 September 2020 – Exhalation Technology has appointed The Sage Group to lead the partnering program for its novel diagnostic test for Covid-19 in exhaled breath condensate. This is a rapid (<5 minutes) test of high specificity and sensitivity for Covid-19, meeting the need for testing in a wide range of environments.
CoronaCheck™ for Covid-19
Coronavirus spreads through breath, and scientific studies indicate that testing for Covid- 19 in breath could offer true convenience and high reliability. At the Cambridge based start-up Exhalation Medical Technology, we are innovators in breath tests, applying rapid, non-invasive Point of Care technology to a range of respiratory diseases. This is now being applied to coronavirus testing and we are proud to announce funding for the project by Innovate UK, the UK’s innovation agency.